Lymphoma Treatment | Lymphatic Cancer

Posts tagged "lymphoma treatment"

Lymphoma – Symptoms And Prevention

Diseases like tumors, sarcoma, melanoma, and lymphoma have threatened many human lives. When we look on any type of cancers we will find many experts are doing research to find out the best cures for the patients. Besides this there are experts in prostate cancer and in acoustic neuroma that have been successful in introducing some form of treatment but still there is much more progress required to treat the large number of patients. Let us move to the disease of Lymphoma, which has become one of the common causes of fatalities these days. Hopefully those suffering from this condition will get some basic help.

What is Lymphoma?

Lymphoma is a type of building up disease which disturbs the cycle of lymphatic system. Lymphatic system is a part of immune system, a system which helps our body to fight against bacteria and viruses. When the system gets disturbed, the disease starts to spread because there is no other way to fight back the bacteria and constant virus attacks inside the body. It is a kind of disease which when spreads in any part of the body starts to decay that section. It is really a cursing disease and has put many lives to suffer.

Often we come to hear about the “Lymph Nodes”. This is the section where lymphoma tends to attack. These nodes are swollen at the time we are carrying any bacterial infection. A time comes when the cells in this section start to develop and their rapid growth curse the section. The final stage of this development results in Lymphoma.

Causes & Symptoms:

With the research, the experts have not declared any definite causes for the diseases as every patient is having his or her own symptom for the disease. However, there are some general risk factors which can give you a bit sign but still there is a deep diagnosis required to testify the suspected patient.

Age:

There are two age groups who are found with the disease. The first percentile is reported in old people, who are above the age of 60. In children it is recorded in the kids who have a weak or pre-mature immune system.

Already disturbed or weak immune system:

The person with a weaker immune system can easily come under the influence of Lymphoma. A weak immune system itself invites this disease after that it spreads rapidly.

Inherited:

Lymphoma can be inherited. If anyone had the same syndrome in his or her family, then it increases the likelihood for the disease to come back to the person.

Other diseases of stimulation:

There are some diseases which also invites the urgency of Lymphoma. The most common are HIV Aids and hepatitis C.

Prevention:

As the disease does not have any confirmed symptoms, the choices of prevention are also very limited. According to the experts’ advice, you can prevent yourself by eradicating the risk factors. There are some automatic risk factors which you cannot avoid, like inheritance factor. But you can avoid some risk factors which are in your hand like avoid smoking etc.

Stewart Wrighter has been searching the term prostate cancer New York in order to find the latest treatments because he is authoring an article on the subject for a major news magazine. He searched the term acoustic neuroma New York in order to find a specialist in the area.

Living with Lymphoma: A Patient’s Guide
by: Elizabeth M. Adler
publisher: The Johns Hopkins University Press, published: 2005-09-30
ASIN: 0801881803
EAN: 9780801881800
sales rank: 346545
price: $9.25 (new), $0.85 (used)

When neurobiologist Elizabeth M. Adler was diagnosed with non-Hodgkin lymphoma, she learned everything she could about the disease, both to cope with the emotional stress of being diagnosed and to make sure she made the best possible decisions for her treatment. In Living with Lymphoma, she combines her knowledge of lymphoma—both scientific and personal—with the desire to help other patients come to grips with this complex, and often baffling, disease.

Adler thoroughly explains the disease, describing the many different kinds of Hodgkin and non-Hodgkin lymphoma, the wide range of symptoms, and the various treatment options available. Convinced that understanding lymphoma’s biological basis will help patients make better treatment decisions, Adler explains basic cell biology and how the immune system functions. Readers will gain sufficient background to understand and evaluate medical literature, and to ask their physicians questions specific to their own needs.

In the introduction, Dr. Michael R. Bishop of the National Institutes of Health provides a physician’s perspective on the delicate nature of doctor-patient relationships in the context of a life-threatening disease—especially the importance of patient education and open communication in making decisions about treatment options and quality of life.

Drawing on her scientific expertise and personal journey—as well as her empathy, passion, and humor—Adler has created a valuable guide for people with lymphoma and the people caring for them.

Alternative Cancer Treatment Guide

How To Successfully Treat Cancer Using Inexpensive, Proven, Natural Therapies.

Lymphatic Cancer Survival Rate

There are two types of lymphatic cancer viz., Hodgkin lymphatic cancer and Non-Hodgkin lymphatic cancer. The Hodgkin lymphatic cancer is caused due to the abnormal cells called Reed-Sternberg. The non-Hodgkin lymphatic cancer is a cancer caused without the abnormal cell called Reed-Sternberg. The Hodgkin lymphatic cancer has been found to affect mostly young adults . The incidence rate of males getting the Hodgkin lymphoma is higher than that of the females. According to the research, the Hodgkin lymphoma is common among young people of the age less than 20. In the year 2006, there were 1.1 per 100,000 children, who were affected by the Hodgkin lymphoma. The Hodgkin lymphoma is most common in children, as compared to the non-Hodgkin lymphoma.

Lymphatic Cancer Survival and cure rates

More aggressive forms of non-Hodgkin lymphomas may be fatal, but have a higher likelihood of being cured with chemotherapy. The lower-grade lymphatic cancers have a longer lymphatic survival rate, often 10 or more years, but are often not curable.

Lymphatic Cancer Survival rates by type

Cutaneous anaplastic large cell has the best prognosis, with a 78 percent, five-year survival rate, while peripheral T-cell, anaplastic large T/null cell and angioimmunoblastic lymphoma have a five-year survival rate together of 38 percent to 43 percent. Extranodal NK/T-cell lymphatic cancer and enteropathy-type lymphatic cancer are in the lowest five-year survival rate category, with a prognosis of 22 percent to 24 percent.

Survival rates for non-Hodgkin lymphoma

These factors are important because they allow doctors to plan treatment better than they could if treatment were based only on the type of lymphoma (the pathology report) and staging information.

Each poor prognostic factor is assigned 1 point. People without any poor prognostic factors would have a score of 0, while those with all of the poor prognostic factors would have a score of 5. The index divides people with lymphomas into 4 risk groups:

Low (0 or 1 poor prognostic factors)
Low intermediate (2 poor prognostic factors)
High intermediate (3 poor prognostic factors)
High (4 or 5 poor prognostic factors)

In the studies used to develop the index, about 75% of people in the lowest risk group lived longer than 5 years, but only about 30% of people in the highest group lived at least 5 years. These numbers show the difference the index scores can make. But newer treatments mean that survival rates are likely to be higher now.

The IPI allows doctors to plan treatment better than they could just based on the type and stage of the lymphoma. This has become more important as new, better treatments have been found that sometimes have more side effects. The index helps doctors figure out whether these treatments are needed. It also gives patients information about the outlook for their future.

Hodgkins disease survival rate

These are the 5-year survival rates.

Stage I: 90% to 95%

Stage II: 90% to 95%

Stage III: 85% to 90%

Stage IV: Around 80%

Since 1960 the Hodgkins disease survival rate has doubled from 40% to over 86% caused by the improvement of the types of treatments.

The cause of Hodgkins disease is unknown. Many studies are trying to change that.
Decadron Diary: A Family’s Journey Through Hodgkin’s Disease
by: Karen Kondor
publisher: Xlibris, Corp., published: 2011-04-20
ASIN: 1462857450
EAN: 9781462857456
sales rank: 3477244
price: $14.10 (new), $45.80 (used)

Based on a collection of emails, Decadron Diary is a combination memoir and self-help book that details one family’s journey through cancer treatment. At once serious and humorous, Decadron Diary epitomizes the rollercoaster ride that is the daily experience of anyone facing cancer, whether that person is the patient, the family member, the physician, the nurse, the psychologist or anyone else who crosses paths with cancer.

Hodgkin Lymphoma
publisher: Lippincott Williams & Wilkins, published: 2007-05-18
ASIN: 078176422X
EAN: 9780781764223
sales rank: 1105253
price: $29.47 (new), $29.46 (used)

The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up.

This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment options—including combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantation—and offer guidelines for treatment selection. Full consideration is given to late effects of therapy and clinical trials for assessing quality of life in patients.

This edition includes complete access to the fully searchable online text of the entire book with all the images.

Targeted Therapy For Malignant Lymphoma Treatment

Targeted therapy is a type of medication that blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with rapidly dividing cells (e.g. with traditional chemotherapy). Targeted cancer therapies may be more effective than current treatments and less harmful to normal cells.

The definitive experiments that showed that targeted therapy would reverse the malignant phenotype of tumor cells involved treating Her2/neu transformed cells with monoclonal antibodies in vitro and in vivo by Mark Greene’s laboratory.

Some have challenged use of the term, stating that drugs usually associated with the term are insufficiently selective. The phrase occasionally appears in scare quotes.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. Monoclonal antibody therapy is one type of targeted therapy used to treat adult non-Hodgkin lymphoma.

Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the laboratory from a single type of immune system cell. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Monoclonal antibodies that have been joined to radioactive material are called radiolabeled monoclonal antibodies.

Targeted Cancer Therapy: A Handbook for Nurses
by: Gail M. Wilkes
publisher: Jones & Bartlett Publishers, published: 2009-12-30
ASIN: 0763772119
EAN: 9780763772116
sales rank: 1709098
price: $8.00 (new), $4.82 (used)

Targeted Cancer Therapy: A Handbook for Nurses is an essential guide for nurses interested in the latest discoveries in oncology. Covering the most recent treatment option of transforming cancer into a chronic illness, Targeted Cancer Therapy provides nurses with the information they need to understand this and future developments in the field. This comprehensive but easy-to-understand text takes nurses through foundational concepts in cell and normal biology that are crucial to understanding cancer and targeted therapy. Featuring relevant analogies and easy-to-follow discussions on malignant transformation, metastases, cellular pathways, and toxicities, this one-of-a-kind text enables nurses to quickly get up to speed on key topics and develop care plans for oncology patients. Accessible, comprehensive, informative, Targeted Cancer Therapy is a must-read for every oncology nurse.

Targeted Cancer Therapy (Current Clinical Oncology)
publisher: Humana Press, published: 2009-12-09
ASIN: 1607615983
EAN: 9781607615989
sales rank: 2695466
price: $32.95 (new), $32.99 (used)

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.

Targeted Therapeutics in Melanoma (Current Clinical Oncology)
publisher: Humana Press, published: 2011-12-31
ASIN: 1617794066
EAN: 9781617794063
price: $219.00 (new)

Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.

Targeted Radionuclide Tumor Therapy: Biological Aspects
publisher: Springer, published: 2010-11-29
ASIN: 9048179564
EAN: 9789048179565
sales rank: 4437604
price: $209.42 (new), $296.04 (used)

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. The expanding array of new targeting molecules (recombinant antibodies or peptides) may increase the therapeutic efficacy. The title of this book “Targeted Radionuclide Tumor Therapy – Biological aspects” was selected to reinforce the concept that a major focus was devoted to understanding the biological effects of targeting and radiation. Furthermore, our rapidly expanding knowledge of low dose-rate effects, different types of cell death, autosensitization and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future. The development of targeted therapy is a true multidisciplinary enterprise involving physician scientists from the fields of nuclear medicine, radiation therapy, diagnostic radiology, surgery, gynaecology, pathology and medical oncology/haematology. It also involves many preclinical scientists working with experimental animal models, immunochemistry, recombinant antibody technologies, radiochemistry, radiation physics and basic cell biology. It is the ambition of the editors to enable deeper insights in the process of improving targeted therapy. We believe that the time now has come when targeted therapy can soon be added to standard oncology treatment regimens.

Targeted Therapies in Rheumatology
by: Josef S. Smolen
publisher: Informa Healthcare, published: 2002-12-19
ASIN: 1841841579
EAN: 9781841841571
sales rank: 8844859
price: $55.50 (new), $55.48 (used)

This textbook serves as a comprehensive reference on the latest science underlying the development of biological therapies, as well as their use in animal and human studies of rheumatological disease. Part A covers targets of emerging therapies – targeting/manipulating cells, targeting cell surface receptors, targeting cytokines, inflammatory mediators and transcription factors, and targeting plasma molecules. Part B then examines the use and implementation of these new therapies in the clinic, covering their use in treating specific rheumatological conditions. Part C discusses issues relating to study design and regulatory issues in the US and Europe.

Targeted Therapies in Oncology
publisher: Informa Healthcare, published: 2007-09-18
ASIN: 084939371X
EAN: 9780849393716
sales rank: 3450547
price: $195.95 (new), $166.51 (used)

Targeted therapy is one of the most burgeoning areas of development in cancer research. Increasing knowledge in tumor formation and growth at the molecular level has generated a broad array of therapeutic options, including signal transduction inhibition, anti-angiogenic and anti-vascular agents, cell cycle inhibitors, telomerase and telomere interacting agents, apoptosis inducers, and anti-invasive agents. This book presents an authoritative overview of existing molecular targeted therapies, their relevance and role for specific tumors, and their clinical efficacy and impact on patient treatment.

Curel Targeted Therapy Deep-Penetrating Foot Cream 3.5 Oz (Pack of 4)
publisher: Curel
ASIN: B005FSRQA4
EAN: 0609132533211
sales rank: 20652
price: $15.89 (new)

Reference οf malignant lymphoma

Malignant Lymphomas (Atlas of Clinical Oncology.)
by: Michael L. Grossbard MD
publisher: pmph usa, published: 2002-01-01
ASIN: 1550091522
EAN: 9781550091526
sales rank: 2147604
price: $8.97 (new), $5.99 (used)

The experts address the disease group by type – indolent B-cell lymphoma, diffuse large cell lymphomas, Burkitt’s/high-grade non-Hodgkin’s lymphoma – as well as the key therapies of chemotherapy, monoclonal antibody, radiation, vaccine, hematopoietic stem cell transplants and more. This text’s multi-author approach is a necessity now that management and classification of lymphoma have grown so complex. Malignant Lymphomas will be a valuable resource in the practice of those seeing patients with the disease, as well as a springboard for the continued inquiry into advances being made into the pathophysiology, diagnosis and management of lymphoma.

Malignant Lymphoma
publisher: Hodder Arnold Publishers, published: 2000-12-15
ASIN: 0340742070
EAN: 9780340742075
sales rank: 4365384
price: $151.13 (new), $1.07 (used)

This text discusses the full range of scientific and clinical developments that have occurred in the investigation and treatment of Hodgkin’s disease and non-Hodgkin’s lymphomas. With contributions from around the world, it covers both current views and likely future developments, and addresses a broad spectrum of clinical care, from the routine to the highly experimental.
Malignant Lymphoma: Biology, Natural History and Treatment
by: Alan Clifford Aisenberg
publisher: Lea & Febiger, published: 1991-07
ASIN: 0812113829
EAN: 9780812113822
sales rank: 5103857
price: $8.50 (new), $0.06 (used)

Discusses the clinical aspects of lymphoma, classification and pathology, with emphasis on immunology and molecular genetics. Tabular and graphic materials document the natural history and detail treatment recommendations.
Malignant Lymphomas: Biology and Treatment: An Update (ESO Monographs)
publisher: Springer, published: 1995-11-10
ASIN: 3540601228
EAN: 9783540601227
price: $123.00 (new), $49.98 (used)

In the last few years a good deal of information related to the biology and treatment of malignant lymphomas has been accumulated and published in journals and monographs. There is, however, no book that gives a concise and objective update of this information or presents a general survey of the subject. The contributors to this book are international authorities, and on the basis of their personal experience and data from the literature they have written a high-level update on malignant lymphomas which will be of interest to both specialists and nonspecialists.

Drawing on her scientific expertise and personal journey—as well as her empathy, passion, and humor—Adler has created a valuable guide for people with lymphoma and the people caring for them.
Johns Hopkins Patients’ Guide to Lymphoma
by: Aditya Bardia
publisher: Jones and Bartlett Publishers, Inc, published: 2010-03-12
ASIN: 076378513X
EAN: 9780763785130
sales rank: 303744
price: $10.56 (new), $14.30 (used)

Johns Hopkins Patients’ Guide to Lymphoma is a concise, easy-to-follow how to guide that puts you on the path to wellness by explaining lymphoma treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman’s terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

100 Questions & Answers About Lymphoma, Second Edition
by: Peter Holman
publisher: Jones and Bartlett Publishers, Inc., published: 2009-12-09
ASIN: 0763744999
EAN: 9780763744991
sales rank: 816511
price: $8.49 (new), $7.77 (used)

EMPOWER YOURSELF! Written by oncology experts with over 20 years of experience, 100 Questions and Answers About Lymphoma, Second Edition provides authoritative answers to your questions on lymphoma. Featuring the information you need in one concise, easy-to-read volume, 100 Questions and Answers About Lymphoma, Second Edition is an invaluable resource for newly diagnosed patients, survivors, friends or relatives of either. Now, in its Second Edition, this newly updated text features information on the latest, cutting-edge treatments and medication, Hodgkin s and Non-Hodgkin s lymphoma, natural killer cells, T-cell lymphoma, autoimmune diseases, and much more! Comprehensive, insightful, compact, 100 Questions and Answers About Lymphoma, Second Edition is an essential guide for anyone coping with the physical and emotional turmoil of this disease. Key features include: Diagnosis and classification of lymphoma; Staging and treatments; Coping with lymphoma; Alternative and complimentary therapies; Working during treatment

Skin Lymphoma: The Illustrated Guide
by: Lorenzo Cerroni
publisher: Wiley-Blackwell, published: 2009-09-29
ASIN: 1405185546
EAN: 9781405185547
sales rank: 522386
price: $153.21 (new), $98.99 (used)

Skin lymphomas are relatively rare and can be easily misdiagnosed as psoriasis or dermatitis. These lymphomas can be fatal. Consequently, those in training in dermatology and pathology need to have a good understanding of the clinical presentations and the pathological correlates of this challenging disease.

This updated edition provides:

A full-colour illustrated text and atlas that combines pathology with clinical features and treatment
updated nomenclature according to WHO/EORTC and WHO classifications
Images to expand the diagnostic potential
Cases to enhance the scope for teaching and learning

Non-Hodgkin Lymphomas
publisher: Lippincott Williams & Wilkins, published: 2009-11-05
ASIN: 0781791162
EAN: 9780781791168
sales rank: 1282740
price: $169.41 (new), $153.57 (used)

Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic.

This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders.

A companion Website includes the fully searchable text and downloadable images.

Medifocus Guidebook on: Non-Hodgkin’s Lymphoma
by: Medifocus.com
publisher: CreateSpace, published: 2011-01-12
ASIN: 1453878130
EAN: 9781453878132
sales rank: 1819166
price: $22.01 (new), $30.67 (used)

The MediFocus Guidebook on Non-Hodgkin’s Lymphoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Hodgkin’s Lymphoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Hodgkin’s Lymphoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks. This Guidebook was updated on January 12, 2011.

Understanding Leukemias, Lymphomas and Myelomas, Second Edition
by: Tariq I. Mughal
publisher: Informa Healthcare, published: 2010-08-11
ASIN: 1841846945
EAN: 9781841846941
sales rank: 2034221
price: $149.09 (new), $147.49 (used)

A brand-new edition of the bestselling guide to hematologic malignancies.

An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.

Following on the successful steps of the first edition, this Second Edition covers:

various types of leukemias, lymphomas, and myelomas
utilizing stem cell transplantation
side-effects of various treatments
future prospects for leukemia, lymphoma, and myeloma
targeted therapies and history of the cancers
information and support sources for patients

Lymphoma in Dogs: Prednisone Treatment

Lymphoma in dogs is a cancer of lymphoid cells. As these cells circulate throughout the body via the lymphatic system, lymphoma can develop on any part of the body. Tumors can occur in the lymph nodes, gastrointestinal tract, chest, skin, spleen, liver and bone marrow.

The condition can be found in dogs of various breeds and ages. It is however most common in certain breeds such as Airedale Terrier, Basset Hound, Boxer, German Shepherd and Rottweiler. Lymphoma tends to occur in middle aged or older dogs.

Treatment for Lymphoma in Dogs

Chemotherapy is the main treatment for lymphoma in dogs.

Prednisone therapy is the other dog lymphoma treatment. Prednisone is a corticosteroid that can kill tumor cells. However, it is not as effective as chemotherapy for treating lymphoma in dogs. Prednisone is primarily used to manage symptoms of the disease.

When to Use Prednisone as Treatment for Lymphoma in Dogs

The decision to use prednisone for treating lymphoma in dogs depends on a number of factors. The main one is cost as it tends to be less expensive than chemotherapy.

Some pet owners are not in favor of chemotherapy due to its toxicity. They may opt for prednisone therapy as it can help to relieve symptoms and make their dogs more comfortable in the short term.

Side Effects of Prednisone

Like most drugs, there are some side effects to using prednisone for treating lymphoma in dogs. Interestingly, some of these side effects are similar to those experienced by humans who also use the drug.

The side effects of prednisone include:

- Increased thirst and hunger: Dogs will eat more than usual and urinate more frequently due to increased water intake.

- Diabetes: Prednisone can cause insulin resistance. This results in high glucose levels in the blood that can eventually cause diabetes.

- Loss of hair and changes in coat: Hair loss is a frequent side effect of using prednisone on dogs. In some cases, not only does the dog’s coat become thinner, the healthy sheen also disappears. Some dogs will also develop hard to heal skin infections.

- Gastrointestinal problems: These include diarrhea, stomach ulcers and even vomiting.

- Cushing’s disease: This condition can be quite serious. Canine Cushing’s disease results in an overproduction of cortisone. This hormonal imbalance has a number of symptoms, such as an impaired immune system, weight gain or loss and increased thirst.

- Changes in behavior: Prednisone use also results in dogs becoming restless and even aggressive.

Dogs treated with prednisone alone usually live for 2-3 months only. When prednisone is given in combination with other chemotherapy drugs, the expected lifespan is about a year.

V879EFQ3MDQZ

Malignant Lymphoma : Treatment, Diagnosis And Prevention

Malignant lymphoma are a group of cancers in which cells of the lymphatic system become abnormal and start to grow uncontrollably. Because there is lymph tissue in many parts of the body, lymphomas can start in almost any organ of the body.

The diagnosis of malignant lymphoma requires the presence of malignant lymphocytes in a biopsy of lymph node or extra-lymphatic tissue. An excisional lymph node biopsy is essential for complete diagnostic assessment. If a whole lymph node is not obtainable, sufficient incised tissue from an extra-lymphatic site can be diagnostic but is less desirable. Fine needle aspiration biopsy (see Appendix I: Biopsy Procedures) is not sufficient for the initial diagnosis of malignant lymphoma.

The following histologic sub-classification of the malignant lymphomas is an adaptation of the Working Formulation and the WHO/REAL classification (Jaffe E, Tumours of Hematopoietic and Lymphoid Tissues, World Health Organization Classification of Tumours, IARC Press, 2001) and is based on the light microscopic interpretation complemented by special stains, immunophenotyping, cytogenetics and other information as available. The specific lymphomas are divided into three major groups for treatment planning.

Treatment of malignant lymphoma.

Malignant lymphomas are increasing in frequency for unknown reasons. We know today that they constitute a big family of tumours of lymphoproliferative origin, which can be very different one from the other in terms of morphology, biology, and clinical behaviour. Some of them need very specific treatments and it is therefore important that a clear diagnosis is obtained and that the treatment is administered by specialised doctors. Although the new WHO classification has abolished the concepts of low-grade and high-grade lymphomas, it remains true that some lymphatic cancers exhibit indolent behaviour and cannot be cured, while other aggressive lymphomas can be cured by modern therapy. The cornerstone of treatment remains chemotherapy and, to a minor extent, radiotherapy. New treatment modalities such as the use of monoclonal antibodies, high-dose therapy or allogenic transplantation have improved the treatment results in the last decade. In this article we offer a summary of the most important concepts which are of interest for practising physicians.

Diagnosis of malignant lymphoma

An immunoperoxidase method for distinguishing lymphomas from nonlymphoid neoplasms with monoclonal antibody T29/33 is described. This antibody recognizes a 200,000-dalton pan-hematopoietic glycoprotein antigen. Staining in nearly 200 hematopoietic tumors was positive for T29/33, although three of six plasmacytomas were negative for this antibody. Five undifferentiated tumors that were proved to be lymphomas by subsequent electron microscopic and immunohistologic studies were positive for T29/33. Conversely, 11 of 12 undifferentiated tumors with ultrastructural and clinical features of carcinoma or sarcoma were T29/33-negative. The only exception was one sarcoma that was T29/33-positive. Thus, monoclonal antibody T29/33 is a valuable tool for characterizing neoplasms that cannot be diagnosed by histopathologic examination alone.

Malignant lymphoma prevention

Preventive measures, when initiated early, may help patients with NHL/CLL who have a higher risk of developing NMSC in the future. Patients who have significantly sun-damaged skin with multiple actinic keratoses may be candidates for aggressive regional treatments with either topical chemotherapy or photodynamic therapy. Aggressive treatment of these chronically sun-damaged sites may prove beneficial in decreasing the development and aggressive behavior of NMSC in these patients. Effective sun-protective efforts in patients with NHL/CLL is also important.

A patient with NHL/CLL that sun protects rigorously on a daily basis may be at risk for vitamin D deficiency. Patients with NHL/CLL and a history of multiple aggressive and/or recurrent NMSC may be considered for systemic retinoids and perhaps other forms of preventive systemic chemotherapy.

Female and male infants have essentially the same overall cancer incidence rates, but white infants have substantially higher cancer rates than black infants for most cancer types. Relative survival for infants is very good for neuroblastoma, Wilms’ tumor and retinoblastoma, and fairly good (80%) for leukemia, but not for most other types of cancer.

Tips on Cancer Prevention

1. Limit alcohol.

2. Maintain a healthy weight.

3. Stay physically active.

4. Consider limiting fat in your diet.

5. Avoid prolonged exposure to the sun and other UVA/UVB sources, such as tanning beds.

6. Use ample amounts of sunscreen or sunblock with an SPF of 15 or higher every day, even if it is cloudy.

7. Wear large framed or wrap-around sunglasses to protect the eye area.

8. Have your skin checked by a dermatologist regularly.

9. Do avoid all poisonous chemical substances such as cigarettes, alcohol, car exhaust fumes, as well as fumes belched by factory chimneys, which are very toxic.

10. Anilin is a carcenogenic substance used for colouring food, so try to avoid artificially dyed foods and instead look for natural foods.

Reference of malignant lymphoma

Malignant Lymphomas: Biology and Treatment: An Update (ESO Monographs)

Malignant Lymphomas (Atlas of Clinical Oncology.)

Malignant Lymphomas is a volume in the acclaimed American Cancer Society Atlas of Clinical Oncology series. Dr. Grossbard and his team have summarized current knowledge on the pathology, epidemiology, molecular biology, presentation and management of patients with both non-Hodgkin’s lymphoma and Hodgkin’s disease. The experts address the disease group by type – indolent B-cell lymphoma, diffuse large cell lymphomas, Burkitt’s/high-grade non-Hodgkin’s lymphoma – as well as the key therapies of chemotherapy, monoclonal antibody, radiation, vaccine, hematopoietic stem cell transplants and more. This text’s multi-author approach is a necessity now that management and classification of lymphoma have grown so complex. Malignant Lymphomas will be a valuable resource in the practice of those seeing patients with the disease, as well as a springboard for the continued inquiry into advances being made into the pathophysiology, diagnosis and management of lymphoma.

Malignant Lymphoma

[table id=4 /]

Canine Lymphoma Treatment – What Are the Options?

Canine lymphoma is a common malignant cancer in middle aged dogs. Although it can affect any breed, Golden Retrievers are more at risk of developing this type of cancer.

What are the treatment options for canine lymphoma?

Chemotherapy Treatment

Canine lymphoma is highly responsive to chemotherapy. Multi-agent chemotherapy protocols that use a combination of drugs are more effective than single-agent (single drug) chemotherapy protocols.

At least 80% of dogs treated with multi-agent chemotherapy protocols go into remission for at least a year. Although second remission may be possible, it is shorter than the first remission. Some cancer cells have become resistant to the initial drugs used so finding the right protocol for the following remission is only by trial and error. There is no one protocol that works the best.

Although multi-agent protocols increase life span, they are more toxic and costly than single-agent protocols.

The success of chemotherapy treatment depends on the location of the tumor, clinical staging and well-being of the dog at the time of diagnosis. Lymphoma of the thymus (mediastinal lymphoma) and bone marrow reduce the chances of remission. Dogs that don’t feel ill or display any clinical signs (vomiting, diarrhea, etc) when first diagnosed with lymphoma, seem to do better with chemotherapy treatment.

Most dogs do not suffer from side effects of chemotherapy. The common side effects include vomiting, loss of appetite, diarrhea and low blood cell count. Even if a dog has side effects, they are usually mild. It is rare for dogs to suffer from serious side effects that need hospitalisation.

Prednisone Treatment

Prednisone is a type of corticosteroid that provides 2-3 months of remission. It is used when the dog is not a candidate for chemotherapy or the pet owner cannot afford the high cost of chemotherapy treatment.

Although not as effective as multi-agent chemotherapy protocols, prednisone alone can make the dog’s life more comfortable. It does not contribute much to extending the life span.

Prednisone treatment reduces the effectiveness of chemotherapy, so should not be used prior to a chemotherapy treatment.

Canine Bone Barrow Transplant

This treatment has been widely used in human patients with lymphoma. North Carolina State University’s College of Veterinary Medicine is the first university to offer this treatment for canine lymphoma.

Healthy stem cells are harvested from the peripheral blood and bone marrow. The dog has to undergo total body radiation to kill off remaining cancer cells before the harvested stem cells are transplanted into it.

The cure rate is at least 30%. For now, bone marrow transplant may be the only canine lymphoma treatment that offers a cure.

If your dog has lymphoma, your vet can advise you on the best treatment option. It’s up to you to decide if you want your dog treated. Some questions to ask yourself are:

- can you afford the cost of treatment?

- how old is your dog?

- is your dog currently suffering and in pain?

- do the benefits outweigh the risks of treatment?

Posts tagged "lymphoma treatment"

Lymphoma – Symptoms And Prevention

Recommended Reading

Lymphatic Cancer Survival Rate

Recommended Reading

Targeted Therapy For Malignant Lymphoma Treatment

Recommended Reading

Reference οf malignant lymphoma

Recommended Reading

Lymphoma in Dogs: Prednisone Treatment

Recommended Reading

Canine Lymphoma Treatment – What Are the Options?

Recommended Reading

Recent Post

Less Hair than Your Father – Humorous Cancer Card Card

Your Friend is Fighting Cancer – Humorous Kitty Archer Card

Your Brother is Fighting Cancer – Humorous Kitty Archer Card

Cancer Free: ocean sunrise Card

Less Hair than Your Brother – Humorous Cancer Card Card

Your Sister is Fighting Cancer – Humorous Kitty Archer Card

Your Daughter is Fighting Cancer – Humorous Kitty Archer Card

Archives

Categories

Less Hair than Your Father - Humorous Cancer Card Card

Your Friend is Fighting Cancer - Humorous Kitty Archer Card

Your Brother is Fighting Cancer - Humorous Kitty Archer Card